Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients

Modified Dosing Regimen:
A small tweak in the dosing regimen of Eli Lilly's Alzheimer's disease drug Kisunla has significantly reduced brain swelling in patients.

ARIA-E Risk Reduction:
The incidence of ARIA-E (a type of brain swelling) was reduced from 24% in the standard dosing group to 14% in the modified titration group.

Gradual Dosing:
The modified dosing regimen involves a more gradual increase in the size of the first three infusions, which has been shown to cut the rate of brain swelling over six months of treatment.

Regulatory Submission:
Eli Lilly plans to submit the data to drug regulators, seeking a potential label update for Kisunla.

Amyloid Reduction:
The dosing change had little impact on the amount of amyloid removed by 24 weeks, with volunteers in the modified group seeing a 67% reduction.